PAM Pathway Inhibitors Prolong Survival in Endocrine-Resistant Advanced Breast Cancer
Targeted therapies inhibiting the PI3K, AKT, and mTOR signaling axis demonstrate significant progression-free survival benefits for patients with endocrine-resistant, hormone ...

